Alzheimer’s disease and type 2 diabetes mellitus: a systematic review of proteomic studies

• Autor(a) principal: Jéssica Diniz Pereira
• Data de Publicação: 2020
• Outros Autores: Vanessa Gomes Fraga, Anna Luiza Morais Santos, Maria Das Graças Carvalho, Paulo Caramelli, Karina Braga Gomes
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: https://doi.org/10.1111/jnc.15166; http://hdl.handle.net/1843/51097; https://orcid.org/0000-0002-1669-3302; https://orcid.org/0000-0002-4786-6990; https://orcid.org/0000-0002-6870-2063
• topic: Alzheimer's disease; Peripheral biomarkers; Type 2 diabetes mellitus; Proteomics; Doença de Alzheimer; Diabetes mellitus; Biomarcadores; Proteômica

Similar to dementia, the risk for developing type 2 diabetes mellitus (T2DM) increases with age, and T2DM also increases the risk for dementia, particularly Alzheimer's disease (AD). Although T2DM is primarily a peripheral disorder and AD is a central nervous system disease, both share some common features as they are chronic and complex diseases, and both show involvement of oxidative stress and inflammation in their progression. These characteristics suggest that T2DM may be associated with AD, which gave rise to a new term, type 3 diabetes (T3DM). In this study, we searched for matching peripheral proteomic biomarkers of AD and T2DM based in a systematic review of the available literature. We identified 17 common biomarkers that were differentially expressed in both patients with AD or T2DM when compared with healthy controls. These biomarkers could provide a useful workflow for screening T2DM patients at risk to develop AD.